SOURCE: Adgero Biopharmaceuticals, Inc.

Adgero Biopharmaceuticals, Inc.

January 05, 2016 08:00 ET

Adgero Biopharmaceuticals to Present at Biotech Showcase™ on January 11, 2016

Presentation Monday, January 11th at 8:00 a.m. PT

PRINCETON, NJ--(Marketwired - January 05, 2016) - Adgero Biopharmaceuticals, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company, leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, announced today that Frank G. Pilkiewicz, Ph.D., Chief Executive Officer, will present at the 8th Annual Biotech Showcase™ conference on Monday, January 11, 2016 at 8:00 a.m. PT in San Francisco, CA.

During his presentation, Dr. Pilkiewicz will provide an overview of REM-001 Therapy, the Company's lead product candidate. REM-001 Therapy has demonstrated promising safety and efficacy results in four Phase 2/3 clinical studies in patients with cutaneous (skin surface) metastatic breast cancer ("CMBC"), the majority of whom have failed radiation therapy. 

Dr. Pilkiewicz will also discuss Adgero's clinical and regulatory strategy to advance REM-001 Therapy, including the Company's anticipated filings for Orphan Drug and Breakthrough Therapy designations in 2016. He will also discuss Adgero's strategy for potential pipeline expansion into additional high-value cutaneous cancer indications.

About Biotech Showcase

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present and meet with investors and potential strategics in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives. The meeting is being held January 11-13, 2016 in San Francisco, CA at the Parc 55, San Francisco, California.

About Adgero

Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous (skin surface) metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy. 

For more information, please visit

Forward-Looking Statements

This press release contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact Information